Bisphenol A (BPA): Fifty Years of a Contested Plastic Chemical

The history of BPA is, in miniature, the history of endocrine disruption science — and of the political and regulatory battles that have surrounded it.

BPA — bisphenol A — was synthesised in 1891. In the 1930s, British biochemist Edward Charles Dodds was systematically testing compounds for oestrogenic activity when he discovered that BPA stimulated oestrogenic responses in rats. He published this finding in 1936 — and then largely set it aside in favour of more potent synthetic oestrogens. One of those more potent synthetic oestrogens was diethylstilbestrol, or DES, which Dodds also discovered in 1938, and which was subsequently prescribed to prevent miscarriage in millions of pregnant women before being banned for that use in 1971 — after it was found to cause vaginal cancer in the daughters of women who had taken it.

BPA, the weaker oestrogen that Dodds had characterised and set aside, was later found to be an excellent precursor for polycarbonate plastic and epoxy resins. By the 1960s, it was in industrial production at enormous scale. The fact that its discoverer had documented its oestrogenic activity in the 1930s was apparently not considered a contraindication for its use in food contact materials — baby bottles, water bottles, can linings, dental sealants.

For decades, BPA's oestrogenic activity was known to toxicologists but considered irrelevant at the low doses encountered in human exposure — a view enshrined in regulatory safety assessments that set acceptable daily intakes based on high-dose animal studies showing no developmental effects.

That view was challenged fundamentally in the mid-1990s, when Frederick vom Saal at the University of Missouri began publishing research showing developmental effects of BPA at extremely low doses — doses orders of magnitude lower than those used in the regulatory studies.

The low-dose controversy vom Saal's finding — that BPA produced enlarged prostates in male mouse fetuses exposed in utero at doses measured in nanograms per kilogram — was alarming precisely because it occurred at doses so low they were within or below the range of typical human exposure. The doses were so low that conventional toxicology, which studied compounds at high doses and extrapolated downward on a linear scale, would predict no effect.

The controversy that followed was bitter and prolonged. Industry-funded studies consistently failed to replicate vom Saal's findings. Independent studies, conducted by academic researchers without industry funding, consistently did replicate them. A 2005 review of the literature found that every industry-funded study on BPA's low-dose effects found no effects, while 94% of non-industry-funded studies found effects — a pattern that matched the manufactured doubt analysis almost perfectly.

The low-dose, non-monotonic problem vom Saal's research also found that BPA's dose-response relationship was non-monotonic — a common property of hormones, where more is not always more potent and the relationship between dose and effect can reverse at different dose ranges. This non-monotonic pattern violates the assumptions underlying conventional toxicological risk assessment, which assumes that if a compound is safe at high doses, it is safe at lower ones.

The regulatory response to BPA's low-dose developmental evidence has been inconsistent across jurisdictions and has failed to keep pace with the independent science.

The FDA maintains that BPA is safe at current exposure levels in food contact applications — a position maintained through periodic re-reviews that have consistently concluded the evidence is insufficient for regulatory action beyond voluntary industry phase-outs.

The European Food Safety Authority conducted its own re-evaluation and in 2023 dramatically revised downward its tolerable daily intake for BPA — by a factor of approximately 20,000 — based on immune system effects found in recent animal studies. This revision effectively concluded that current average human BPA exposure exceeds the tolerable daily intake, raising the question of whether BPA in food contact materials should continue to be permitted in the EU.

The "BPA-free" market shift Consumer pressure, particularly around baby bottles and children's products, drove a market shift toward "BPA-free" products beginning around 2008. This shift has been largely unaccompanied by independent evidence that the BPA replacements — primarily BPS (bisphenol S) and BPF (bisphenol F) — are safer than BPA. Multiple studies have found that BPS and BPF have similar oestrogenic activity to BPA and similar developmental effects in animal models.

This "regrettable substitution" pattern — replacing a compound with structurally similar alternatives that haven't been adequately tested — is one of the central problems of chemical regulation, and BPA's history is its most visible example.

BPA's history contains several lessons that are directly applicable to how consumers evaluate chemical safety claims and how the field of environmental health science continues to develop.

The discoverer-knew problem BPA's oestrogenic activity was documented by its discoverer in 1936. The chemical spent thirty years in commercial development before its oestrogenic activity was reconsidered as relevant to safety. This gap — between known biological activity and safety regulation — is not unique to BPA. It is a structural feature of how industrial chemicals enter commerce without comprehensive safety evaluation.

The BPS/BPF lesson When choosing products marketed as "BPA-free," the relevant question is not whether they are free of BPA specifically but whether their safety data is better than BPA's was at the time of BPA's peak use. For BPS and BPF, the answer appears to be no — the structural similarity to BPA predicts similar biological activity, and the independent research has found similar effects.

A more useful framework than "BPA-free" is choosing food contact materials with the least chemical migration risk: glass, stainless steel, and ceramics for food storage, heating, and beverage containers. These materials have millennia of human use without the chemical migration concerns of synthetic polymers.

The vom Saal standard vom Saal's insistence on testing BPA at environmentally relevant low doses, against the resistance of an industry-funded research programme that consistently used only high doses, is the methodological standard that the entire endocrine disruption research field has since adopted. His career is an example of what scientific integrity looks like under sustained industry pressure — and the evidence he helped generate has shaped the EFSA's revised BPA assessment and the ongoing regulatory reckoning.